Ensho Joins Race To Develop An Oral Integrin Inhibitor For IBD

Start-Up Licensed Lead Drug From Eisai Subsidiary

 
• By Mandy Jackson

Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.

Rocket launching from wood cube with business icon, Start-up, Creativity, Big idea, Business goals management, Investment
Ensho is launching with a new CEO coming from Telavant • Source: Shutterstock

More from Deals

More from Business